Enliven Therapeutics ELVN Current ratio
Current ratio at other companies
Other financials
Where this comes from
Calculated from Enliven Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's current ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's current ratio?
- Enliven Therapeutics (ELVN) reported current ratio of 40.3× in Q1 2026.
- How has Enliven Therapeutics's current ratio changed year-over-year?
- Enliven Therapeutics's current ratio increased by 91.4% year-over-year, from 21.1× to 40.3×.
- What is the long-term trend for Enliven Therapeutics's current ratio?
- Over 5 years (2020 to 2025), Enliven Therapeutics's current ratio has grown at a 14.6% compound annual growth rate (CAGR), from 14.5× to 28.7×.
- What does current ratio mean?
- Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.